Saturday 17 October 2026
Export SVRA’s income statement to Excel — free account
Savara Inc.
SVRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 14.3%, free cash flow fell 14.1% and total debt rose 1.54%, each against the same quarter a year earlier.
4.45
0.29
−6.12%
Follow SVRA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | 4.60 | 6.21 | 0.69 | 1.00 | 1.03 | 1.02 | 1.52 | 2.82 | 1.89 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | 17.19 | 15.54 | 11.96 | 4.55 | 3.58 | 1.91 | 4.97 | 5.70 | 7.01 | |||||
| People | |||||||||||||||
| People | Employees | 9 | 24 | 34 | 40 | 27 | 22 | 28 | 37 | 59 | 70 | ||||
| Revenue/emp, $m | 0.04 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 0 | — | — | — | 0 | — | — | — | — | — | ||||
| Gross margin, % | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (11) | (33) | (69) | (78) | (50) | (43) | (38) | (55) | (96) | (119) | |||||
| EBT margin, % | (2,820.00) | 0.00 | 0.00 | 0.00 | (19,305.45) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (11) | (30) | (62) | (78) | (50) | (43) | (38) | (55) | (96) | (119) | |||||
| Depreciation | 1 | 1 | 0 | 27 | 1 | 3 | 1 | (5) | (5) | (2) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (5.57) | (1.76) | (1.85) | (1.95) | (0.94) | (0.32) | (0.25) | (0.33) | (0.48) | (0.53) | |||||
| Cash flow | (4.27) | (1.61) | (1.18) | (1.13) | (0.67) | (0.30) | (0.23) | (0.31) | (0.45) | (0.45) | |||||
| Capex | 0.00 | (0.03) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (4.27) | (1.64) | (1.18) | (1.13) | (0.67) | (0.30) | (0.23) | (0.31) | (0.45) | (0.45) | |||||
| Book value | 4.07 | 6.81 | 3.25 | 2.54 | 1.09 | 1.08 | 0.71 | 0.85 | 0.87 | 0.91 | |||||
| Shares, m | 2 | 18 | 33 | 40 | 59 | 134 | 153 | 165 | 198 | 222 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | — | 0.00 | — | — | — | — | — | ||||
| P/S | 0.00 | — | — | — | 0.00 | — | — | — | — | — | |||||
| P/B | 6.10 | — | — | — | 1.06 | — | — | — | — | — | |||||
| EV/Sales | 0.00 | — | — | — | 0.00 | — | — | — | — | — | |||||
| EV/FCF | 428.65 | — | — | — | (0.28) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (8) | (28) | (39) | (45) | (40) | (40) | (35) | (51) | (89) | (101) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (8) | (29) | (39) | (45) | (40) | (40) | (35) | (51) | (89) | (101) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 11 | 92 | 106 | 113 | 77 | 150 | 123 | 155 | 187 | 221 | ||||
| Total debt | 4 | 15 | 25 | 25 | 25 | 26 | 26 | 26 | 27 | 30 | |||||
| Net debt | (9) | (79) | (86) | (97) | (57) | (136) | (100) | (136) | (170) | (206) | |||||
| Shareholders’ equity | 8 | 119 | 108 | 102 | 64 | 144 | 108 | 140 | 171 | 203 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (26.50) | (32.65) | (39.44) | (54.19) | (42.42) | (31.36) | (24.12) | (34.47) | (49.11) | (50.97) | ||||
| ROIC | 0.00 | (46.42) | (199.35) | (978.23) | (412.04) | (288.58) | (304.19) | (852.18) | (3,704.62) | 0.00 | |||||
| ROE | 183.83 | (73.78) | (54.07) | (74.48) | (59.75) | (41.19) | (30.24) | (44.08) | (61.50) | (63.45) | |||||
Negative figures in brackets.
Fiscal years to Dec 2020 · latest quarter Dec 2020
Charts ten years each
Savara Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMTX Immatics N.V. | $1.1B | — (loss-making) | — (loss-making) | +97.71% (above 0%: growing) | n/m | −44.41% (below 0%: shrinking) | 100.00% | (734.95%) | Compare |
| JANX Janux Therapeutics, Inc. | $1.1B | — (loss-making) | — (loss-making) | +2,238.72% (above 0%: growing) | n/m | +150.57% (above 0%: growing) | 100.00% | (308.66%) | Compare |
| MNKD MannKind Corporation | $1.0B | — (loss-making) | — (loss-making) | +42.92% (above 0%: growing) | n/m | −399.41% (below 0%: shrinking) | 72.99% | (0.32%) | Compare |
| SVRA Savara Inc. | $973.9M | — (loss-making) | — (loss-making) | — | n/m | −14.05% (below 0%: shrinking) | 0.00% | 0.00% | |
| MGTX MeiraGTx Holdings PLC | $949.9M | 12.2× | — (loss-making) | +8,608.59% (above 0%: growing) | n/m | +13.06% (above 0%: growing) | 97.77% | 76.04% | Compare |
| CGEM Cullinan Therapeutics, Inc. | $901.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| AKTS Aktis Oncology, Inc. | $890.5M | — (loss-making) | — (loss-making) | — | n/m | −12.77% (below 0%: shrinking) | 100.00% | (853.99%) | Compare |
| ANRO Alto Neuroscience, Inc. | $887.7M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| RIGL Rigel Pharmaceuticals, Inc. | $882.6M | 2.6× | 7.9× | −22.60% (below 0%: shrinking) | −72.07% (below 0%: shrinking) | −229.99% (below 0%: shrinking) | 89.17% | 29.95% | Compare |
| Median of peers | $925.4M | — | — | +97.71% | — | −28.09% | 100.00% | (0.16%) |
Savara Inc. (SVRA) key facts
- Savara Inc. (SVRA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SVRA traded at $4.45, a market capitalization of $973.9 million.
- Return on equity was −63.5% and debt-to-equity 0.21.